Biotech Startups

Longwood Fund is a biotech-focused investment firm that both creates and invests in early-stage biotechnology companies developing therapies for unmet medical needs. The team combines decades of experience in biotech investing, operating, and building, working with companies from seed through clinical proof of concept.

1 investor

Loop Biotech develops biodegradable funeral products made from natural, plastic-free materials, including a living coffin ("Cocoon") and urns. The company targets the funeral and burial industry with sustainable alternatives to traditional caskets and cremation containers.

1 investor

Loop Diagnostics develops an in vitro cellular immunoassay that detects immunosuppression from bloodstream infections, including sepsis, within the first hour of infection to enable earlier treatment. The company serves healthcare providers with a diagnostic tool for early sepsis detection.

1 investor

Lophora is a clinical-stage CNS therapeutics company developing selective 5-HT2A receptor agonists intended to induce neuroplasticity for mood and anxiety disorders. Its lead compound LPH-5 has completed a Phase I trial as a potential at-home treatment for depressive disorders, with additional pre-clinical candidates in its pipeline.

1 investor

LORAI Health develops next-generation transdermal drug delivery technologies for medicines such as hormones, pain therapies, and neurological treatments, with a focus on reliable delivery, patient comfort, and manufacturing resilience. Founded in Australia, it originated in menopausal hormone therapy and works with research, manufacturing, healthcare, and investment partners internationally.

1 investor

LOWENCO manufactures large-scale ultra-low temperature (ULT) freezer systems that replace traditional freezer farms with modular, GMP-compliant cold storage infrastructure for pharmaceutical manufacturers. Its systems maintain temperatures from +20°C to -80°C at scale with N+1 redundancy to protect temperature-sensitive products.

1 investor

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.

1 investor

LTL Pharma acquires and develops long-established pharmaceutical drugs (long-life medications) from originator manufacturers, maintaining consistent supply and quality standards for healthcare providers and patients. The company specializes in managing mature pharmaceutical products with extensive clinical track records.

1 investor

LTZ Therapeutics is an immunotherapy biotech developing treatments for oncology and autoimmune diseases using a myeloid cell engager approach centered on macrophages. It operates a Myeloid Engager Platform and has entered development collaborations with large pharmaceutical companies.

1 investor

Daopei is a group of specialty hospitals in China focused on blood diseases, offering hematopoietic stem cell transplantation, chemotherapy, immunotherapy (including CAR-T), and pathology/laboratory diagnostics for patients with leukemia, lymphoma, myeloma, and other hematological conditions. It operates multiple facilities in Beijing, Shanghai, and Hebei.

1 investor

LubaLabs builds microscopy platforms that measure the mechanical properties of living cells and tissues in 3D at high speed and without labels, aimed at disease modeling and drug discovery applications.

1 investor

Lucid Diagnostics develops tests for the early detection of esophageal precancer using targeted next-generation sequencing, aimed at helping clinicians detect and treat the condition before it progresses to cancer. The company operates a CLIA-certified, CAP-accredited clinical lab licensed by the New York State Department of Health.

1 investor

Lucid Genomics provides a software platform for genomic analysis tailored to clinicians, specializing in long-read sequencing interpretation for rare disease, hereditary cancer, and pharmacogenomics diagnostics. The platform integrates variant calling, prioritization, interpretation, and reporting with HPO-based phenotype matching and advanced visualization tools for structural variants.

1 investor

Lucina Biotherapeutics develops therapeutics to treat aging-related disorders, particularly dry age-related macular degeneration (AMD), by restoring very long-chain polyunsaturated fatty acids (VLC-PUFAs) in tissues through its PUFActive platform. The company employs two approaches: synthetic VLC-PUFA formulations for intravitreal injection and engineered microorganism biofactories for oral delivery.

1 investor

LumaBridge is an oncology-focused contract research organization (CRO) that supports outsourced clinical trials, offering services such as regulatory affairs, clinical operations, data management, medical writing, and biostatistics. It serves emerging biopharma and biotech companies developing novel oncology and immunotherapy treatments.

1 investor

LUMABS BV develops RAPPID, a rapid, one-step immunoassay technology that enables sensitive antibody detection from minimal blood samples for diagnostics and therapeutic monitoring. The company serves immunoassay diagnostic companies, clinical laboratories, biotech organizations, and research groups seeking faster, more sensitive alternatives to traditional ELISA-based assays.

1 investor

Early commercial stage company selling a real-time cell analyzer to pharma companies.

1 investor

Lumen develops orally delivered antibody drugs using engineered spirulina, a patented biologic platform that reduces manufacturing costs and timelines compared to conventional biologics. The company serves biopharma customers seeking alternatives to traditional drug manufacturing.

1 investor

Lumena Pharmaceuticals develops pharmaceutical, nutraceutical, and testing service products using biotechnology, with a focus on ethical practices in research, manufacturing, and distribution across health care markets. The company prioritizes environmental sustainability, reduced chemical use, and responsible innovation in bioavailable product development.

1 investor

Lumencor develops photonics solutions and LED lighting technologies. The company serves research, medical, and industrial markets with specialized light sources.

1 investor

Luminist Labs built a non-invasive diagnostic test for early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). The company was acquired by DiscernDx in 2020.

1 investor

Lumos Diagnostics develops rapid point-of-care diagnostic tests and digital reader platforms for healthcare professionals, targeting infectious and inflammatory diseases. The company offers both customized assay development services and proprietary branded diagnostic solutions.

1 investor

LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk. The company focuses on cardiovascular and blood coagulation therapies for patients requiring anticoagulation.

1 investor

Lunaphore provides spatial biology technology and solutions that enable researchers to integrate spatial analysis into laboratory workflows. The company offers a scalable, precision platform designed to make spatial biology research accessible and mainstream across diverse lab environments.

1 investor